Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 521
- Registration Number
- NCT01026116
- Locations
- 🇨🇳
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2016-09-08
- Lead Sponsor
- Thomas Hatschek
- Target Recruit Count
- 151
- Registration Number
- NCT00957125
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Malmö General University Hospital, Malmö, Sweden
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00954512
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 596
- Registration Number
- NCT00950300
- Locations
- 🇦🇷
Centro Medico San Roque; Oncology Dept, Tucuman, Argentina
🇭🇺Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary
🇲🇽Hospital Privado San Jose; Oncologia, Obregon, Mexico
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
- Conditions
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Centre Jean Perrin
- Target Recruit Count
- 62
- Registration Number
- NCT00933517
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Institut de Cancérologie de la Loire, Saint Priest en Jarez, France
Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Nihon University
- Target Recruit Count
- 450
- Registration Number
- NCT00843934
- Locations
- 🇯🇵
Department of Digestive Surgery, Nihon University School of Medicine, Itabashi, Tokyo, Japan
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 102
- Registration Number
- NCT00841828
- Locations
- 🇪🇸
Hospital General de Granollers, Granollers, Barcelona, Spain
🇪🇸Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00773695
- Locations
- 🇳🇴
Ullevael Sykehus; Dept of Oncology, Oslo, Norway
🇳🇴The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway
🇳🇴St. Olavs Hospital; Kreftavdelingen, Trondheim, Norway
Phase II Neoadjuvant in Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00756470
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
- Conditions
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 91
- Registration Number
- NCT00743964
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.